Scribe Therapeutics, Inc.
Scribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines for cardiometabolic diseases.
SCHEDULE 13GNov 16Latest SEC filing
Nov 12Latest story
Scribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines for cardiometabolic diseases.
November 2026
September 2026
July 2026